COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study to Learn More About Outcomes Reported by Patients Suffering From Type 2 Diabetes Using a Digital Data Collection Tool (DePRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04383041
Recruitment Status : Completed
First Posted : May 11, 2020
Last Update Posted : January 8, 2021
Information provided by (Responsible Party):

Brief Summary:
In this study researchers want to gain more information on patients who are treated with Metformin for their Type 2 Diabetes. Adult female and male patients with a prescription of a Metformin containing drug will be invited to the study in a public pharmacy after the decision for treatment with Metformin has been made by the treating physician. The pharmacist will provide interested participants access to a special phone App and participants are asked to complete via this phone App a questionnaire on their health situation with special focus on their Type 2 Diabetes. This includes questions on complications and self-care activities in relation to their diabetes, questions on quality of life and health history. There will be no extra visit to the treating doctor or a pharmacy. The study is aiming to have the questionnaire completed by 300 participants.

Condition or disease Intervention/treatment
Diabetes Mellitus, Type 2 Other: No intervention

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 32 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 1 Day
Official Title: Digital Collected Patient Reported Outcomes in a Diabetes Cohort
Actual Study Start Date : June 28, 2020
Actual Primary Completion Date : December 9, 2020
Actual Study Completion Date : December 9, 2020

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Patients with Type 2 Diabetes
Patients with Metformin containing prescription drugs will be eligible for participation and consecutively invited to study participation in their pharmacy.
Other: No intervention
Completing questionnaires via ePRO app from their own mobile devices

Primary Outcome Measures :
  1. Summary of Diabetes Self-Care Activities for Diabetes and Kidney Disease (SDSCA) Score [ Time Frame: Baseline ]
    The SDSCA measure is a brief self-report questionnaire of diabetes self-management. It assesses the number of days per week in which respondents engage in diabetes health-related behaviors in the areas of general diet, diabetes-specific diet, physical activity, blood-glucose testing, foot care, and smoking. Minimum score 0. Maximum score 77. Higher scores indicate better self care.

Secondary Outcome Measures :
  1. Association between SDSCA score and demographic/ disease characteristics [ Time Frame: Baseline ]
    Association of Summary of Diabetes Self-Care Activities for Diabetes and Kidney Disease (SDSCA) with demographic and disease characteristics

  2. Acceptance of participation [ Time Frame: Baseline ]
  3. Adherence to documentation [ Time Frame: Baseline ]
  4. Health related Quality of Life-EuroQol five dimensions Questionnaire (EQ-5D) [ Time Frame: Baseline ]
    Descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression).

  5. DTSQ Participation rate [ Time Frame: Baseline ]
    Diabetes Treatment Satisfaction Questionnaire (DTSQ) Number of invited, participating and non-participating patients (reasons for non-acceptance of study participation)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult female and male patients with a valid prescription of a Metformin containing drug will be consecutively invited to the study in a public pharmacy after the decision for treatment with Metformin has been made by the treating physician.

Inclusion Criteria:

  • Adult female or male patient
  • Valid prescription for a Metformin containing drug approved in Germany
  • Decision to initiate treatment with Metformin was made by the treating physician as part of the routine treatment practice
  • Signed informed consent

Exclusion Criteria:

- Not applicable

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04383041

Layout table for location information
Many locations
Multiple Locations, Germany
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT04383041    
Other Study ID Numbers: 21318
First Posted: May 11, 2020    Key Record Dates
Last Update Posted: January 8, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Diabetes Mellitus, Type 2
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases